Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haw ParHAWPF 84 Cash Ratio is 51.46 as of Dec. 2025, which is 22% above its 10-year median of 42.16. GuruFocus rates HAWPF with a GF Score™ of 84/100 and a GF Value™ of $9.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 975 Drug Manufacturers companies, Haw Par ranks better than 99.59% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Haw Par Cash Ratio Related Terms
Haw Par Cash Ratio Historical Data
* Premium members only.
The historical data trend for Haw Par's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Haw Par's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haw Par Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haw Par's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Haw Par's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haw Par (HAWPF) has a Cash Ratio of 51.46 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Haw Par and its competitors. This is 22% above median its historical median of 42.16. Over the past decade, Haw Par's Cash Ratio has ranged from 21.32 to 51.46. According to the industry distribution chart, Haw Par ranks #4 out of 975 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Haw Par's Cash Ratio too high?
Haw Par's current Cash Ratio of 51.46 is 22% above median its 10-year median of 42.16. Over the past 10 years, this metric has ranged from a low of 21.32 to a high of 51.46. The Drug Manufacturers industry median Cash Ratio is 0.60. Haw Par's value of 51.46 is 8476.7% above this industry median. Based on the distribution chart, Haw Par ranks #4 out of 975 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haw Par has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haw Par's Cash Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Haw Par ranks #4 out of 975 companies for Cash Ratio. This places Haw Par in the top 0% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.60. Haw Par's value of 51.46 is 8476.7% above this benchmark. Historically, Haw Par's own Cash Ratio has ranged from 21.32 to 51.46 over the past decade. While the company's 10-year median is 42.16 vs. the industry median of 0.60, Haw Par has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haw Par's current Cash Ratio of 51.46 is 8476.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Haw Par and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haw Par's current Cash Ratio is 51.46, which is 22% above median its own 10-year median of 42.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haw Par stock overvalued right now?
Based on GuruFocus' analysis, Haw Par (HAWPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.28, compared to a current price of $12.58 — trading 35.5% above its estimated fair value. The current Cash Ratio is 51.46, which is 22% above median its 10-year median of 42.16 and 8476.7% above the Drug Manufacturers industry median of 0.60. Haw Par's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Haw Par (HAWPF), the current Cash Ratio is 51.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haw Par (HAWPF) Overvalued in 2026?
Based on GuruFocus' analysis, Haw Par stock appears to be overvalued.
The current stock price of $12.58 is trading 35.5% above its estimated GF Value™ of $9.28.
GuruFocus considers Haw Par to be Significantly Overvalued.
Key valuation signals for HAWPF:
Cash Ratio: 51.46 (22% above median its 10-year median of 42.16)
GF Value™: $9.28 vs. price of $12.58 (35.5% above fair value)
Industry Position: 8476.7% above the Drug Manufacturers median (#4 of 975)
No single metric tells the full story. See the HAWPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haw Par Corp Ltd is a drug manufacturing company that operates multiple brands. The company is to expand its core businesses through product brand extension, strategic alliances, and exploring potential acquisitions. Its operating segments include the Healthcare segment, Investments segment, Property segment, and Leisure segment. The company generates the majority of its revenue from the Healthcare segment. Its Healthcare segment manufactures and distributes topical analgesic products under the Tiger Balm and Kwan Loong brands. Geographically, it generates key revenue from the other ASEAN and other Asian countries.
84GF Score
Get the complete analysis for HAWPF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAWPF has been successfully added to your 
